Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 34,800,000 shares, an increase of 25.1% from the February 28th total of 27,810,000 shares. Based on an average trading volume of 12,260,000 shares, the short-interest ratio is currently 2.8 days. Approximately 3.1% of the company’s shares are short sold.

Teva Pharmaceutical Industries Stock Up 0.1 %

Shares of NYSE TEVA opened at $15.31 on Thursday. The stock has a market capitalization of $17.36 billion, a price-to-earnings ratio of -10.56, a P/E/G ratio of 1.44 and a beta of 0.82. The firm’s 50-day moving average price is $16.81 and its 200-day moving average price is $18.06. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on TEVA shares. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, March 27th. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $44,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth approximately $66,000. Finally, IFP Advisors Inc boosted its stake in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.